Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX

Inclusion Criteria

• •Patients ≥ 18 years of age;
• •Histologically confirmed HER2+ breast cancer;
• •Stage I-III breast cancer without evidence of distant metastases;
• •Being candidate to neoadjuvant/adjuvant therapy and locoregional treatment (surgery +/- radiotherapy);
• •Written informed consent, signed by the patient, to study-specific procedures (the consent will consist of 2 levels: level 1 specifically for patients enrolled in the primary endpoint cohort and level 2 for all patients);